Beaufort Securities Reiterates Speculative Buy Rating for Horizon Discovery Group PLC (HZD)
Horizon Discovery Group PLC (LON:HZD)‘s stock had its “speculative buy” rating reiterated by research analysts at Beaufort Securities in a report issued on Wednesday.
A number of other research analysts have also recently commented on HZD. Numis Securities Ltd restated a “buy” rating and issued a GBX 252 ($3.29) target price on shares of Horizon Discovery Group PLC in a research note on Wednesday, June 1st. Panmure Gordon restated a “buy” rating and issued a GBX 270 ($3.52) target price on shares of Horizon Discovery Group PLC in a research note on Wednesday, June 1st. Finally, N+1 Singer restated a “buy” rating and issued a GBX 194 ($2.53) target price on shares of Horizon Discovery Group PLC in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of GBX 217.25 ($2.84).
Horizon Discovery Group PLC (LON:HZD) opened at 156.00 on Wednesday. The firm has a 50-day moving average price of GBX 160.26 and a 200 day moving average price of GBX 160.78. The stock’s market cap is GBX 146.78 million. Horizon Discovery Group PLC has a 52-week low of GBX 125.00 and a 52-week high of GBX 188.06.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/beaufort-securities-reiterates-speculative-buy-rating-for-horizon-discovery-group-plc-hzd.html
Horizon Discovery Group PLC Company Profile
Horizon Discovery (LSE: HZD) is a world-leading gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. Horizon’s proprietary gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.
Receive News & Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.